12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LY900009: Phase I data

A dose-escalation Phase I trial in 22 patients with advanced cancer showed that 60 mg LY900009 led to grade 3 dose-limiting toxicities (DLTs) of fatigue and diarrhea in 2 patients. The...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >